Globus Medical (GMED)

• Market cap: $7.89B
• 1 day: -0.95%
• 5 days: -5.31%
• 1 month: -4.50%
• 3 months: -19.18%
• 6 months: -30.11%
• Year to date: -28.75%
• 1 year: -12.57%
• 5 years: 21.26%
• 10 years: 127.91%
• Sector: Healthcare
• Industry: Medical Devices

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Employees: 5,300

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

218% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $4.32M

40% more repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 142

33% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 69

2% more funds holding

Funds holding: 494 [Q4 2024] → 504 (+10) [Q1 2025]

1.69% less ownership

Funds ownership: 95.73% [Q4 2024] → 94.03% (-1.69%) [Q1 2025]

5% less funds holding in top 10

Funds holding in top 10: 19 [Q4 2024] → 18 (-1) [Q1 2025]

12% less capital invested

Capital invested by funds: $9.01B [Q4 2024] → $7.92B (-$1.09B) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $68 17% upside
• Avg. target: $74 27% upside
• High target: $80 37% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Truist Securities Richard Newitter	17% upside $68	Hold Maintained	12 May 2025
Piper Sandler Matt O'Brien	37% upside $80	Overweight Maintained	9 May 2025